September 3, 2011 -- Royal DSM and Sinochem won regulatory approval to launch their JV, which calls for Sinochem to pay $291 million for 50% stake in DSM’s anti-infectives unit; Nycomed’s acquisition of Guangdong Techpool Biopharma and a direct sales model in China boosted Nycomed’s Q2 revenues; Merck Serono opened a China lab as part of its planned R&D hub in Beijing; SinoCubate launched as an incubator/investor in mainland China companies; and NexBio released positive data from a Phase II trial of a novel biologic that aims to both treat and prevent infection by all flu strains. More details….
Stock Symbols: (XAMS: DSM) (Xetra: MRK) (OTCBB: SBAT)
